280 related articles for article (PubMed ID: 22086206)
41. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies.
Bellamy WT
Semin Oncol; 2001 Dec; 28(6):551-9. PubMed ID: 11740808
[TBL] [Abstract][Full Text] [Related]
42. Targeting vasculogenesis to prevent progression in multiple myeloma.
Moschetta M; Mishima Y; Kawano Y; Manier S; Paiva B; Palomera L; Aljawai Y; Calcinotto A; Unitt C; Sahin I; Sacco A; Glavey S; Shi J; Reagan MR; Prosper F; Bellone M; Chesi M; Bergsagel LP; Vacca A; Roccaro AM; Ghobrial IM
Leukemia; 2016 May; 30(5):1103-15. PubMed ID: 26859080
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma.
Alexandrakis MG; Goulidaki N; Pappa CA; Boula A; Psarakis F; Neonakis I; Tsirakis G
Pathol Oncol Res; 2015 Sep; 21(4):929-34. PubMed ID: 25743259
[TBL] [Abstract][Full Text] [Related]
44. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents.
Moulopoulos LA; Dimopoulos MA; Christoulas D; Kastritis E; Anagnostou D; Koureas A; Roussou M; Gavriatopoulou M; Migkou M; Iakovaki M; Gkotzamanidou M; Tasidou A; Terpos E
Leukemia; 2010 Jun; 24(6):1206-12. PubMed ID: 20428203
[No Abstract] [Full Text] [Related]
45. An Lysophosphatidic Acid Receptors 1 and 3 Axis Governs Cellular Senescence of Mesenchymal Stromal Cells and Promotes Growth and Vascularization of Multiple Myeloma.
Kanehira M; Fujiwara T; Nakajima S; Okitsu Y; Onishi Y; Fukuhara N; Ichinohasama R; Okada Y; Harigae H
Stem Cells; 2017 Mar; 35(3):739-753. PubMed ID: 27641212
[TBL] [Abstract][Full Text] [Related]
46. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
[TBL] [Abstract][Full Text] [Related]
47. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
48. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis.
Colla S; Tagliaferri S; Morandi F; Lunghi P; Donofrio G; Martorana D; Mancini C; Lazzaretti M; Mazzera L; Ravanetti L; Bonomini S; Ferrari L; Miranda C; Ladetto M; Neri TM; Neri A; Greco A; Mangoni M; Bonati A; Rizzoli V; Giuliani N
Blood; 2007 Dec; 110(13):4464-75. PubMed ID: 17848618
[TBL] [Abstract][Full Text] [Related]
49. Angiogenic activity of mesenchymal stem cells in multiple myeloma.
Wang X; Zhang Z; Yao C
Cancer Invest; 2011 Jan; 29(1):37-41. PubMed ID: 21166497
[TBL] [Abstract][Full Text] [Related]
50. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients.
Colla S; Morandi F; Lazzaretti M; Rizzato R; Lunghi P; Bonomini S; Mancini C; Pedrazzoni M; Crugnola M; Rizzoli V; Giuliani N
Leukemia; 2005 Dec; 19(12):2166-76. PubMed ID: 16208410
[TBL] [Abstract][Full Text] [Related]
51. P-450-dependent epoxygenase pathway of arachidonic acid is involved in myeloma-induced angiogenesis of endothelial cells.
Shao J; Li Q; Wang H; Liu F; Jiang J; Zhu X; Chen Z; Zou P
J Huazhong Univ Sci Technolog Med Sci; 2011 Oct; 31(5):596. PubMed ID: 22038346
[TBL] [Abstract][Full Text] [Related]
52. Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis.
Belloni D; Marcatti M; Ponzoni M; Ciceri F; Veschini L; Corti A; Caligaris Cappio F; Ferrarini M; Ferrero E
Exp Cell Res; 2015 Jan; 330(1):1-12. PubMed ID: 25447443
[TBL] [Abstract][Full Text] [Related]
53. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
54. Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?
Saltarella I; Frassanito MA; Lamanuzzi A; Brevi A; Leone P; Desantis V; Di Marzo L; Bellone M; Derudas D; Ribatti D; Chiaramonte R; Palano MT; Neri A; Mariggiò MA; Fumarulo R; Dammacco F; Racanelli V; Vacca A; Ria R
Neoplasia; 2019 Jan; 21(1):93-105. PubMed ID: 30529074
[TBL] [Abstract][Full Text] [Related]
55. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
[TBL] [Abstract][Full Text] [Related]
56. The role of inflammatory cells in angiogenesis in multiple myeloma.
Ribatti D; Vacca A
Adv Exp Med Biol; 2014; 816():361-76. PubMed ID: 24818730
[TBL] [Abstract][Full Text] [Related]
57. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
Kiziltepe T; Anderson KC; Kutok JL; Jia L; Boucher KM; Saavedra JE; Keefer LK; Shami PJ
J Pharm Pharmacol; 2010 Jan; 62(1):145-51. PubMed ID: 20723011
[TBL] [Abstract][Full Text] [Related]
58. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
59. [Inhibitory effect of curcumin on angiogenesis induced by brain derived neurotrophic factor from multiple myeloma cells].
Wang YD; Hu Y; Sun CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):70-4. PubMed ID: 16584595
[TBL] [Abstract][Full Text] [Related]
60. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
Zarfati M; Avivi I; Brenner B; Katz T; Aharon A
Angiogenesis; 2019 Feb; 22(1):185-196. PubMed ID: 30386953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
